BPC-157
Pending PCACAlso known as: Body Protection Compound-157, Bepecin
Healing & RecoveryLast reviewed: April 28, 2026
A synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice. One of the most widely researched peptides for tissue repair and recovery.
Mechanism of Action
BPC-157 promotes angiogenesis (new blood vessel formation), upregulates growth factor expression, and modulates nitric oxide synthesis. It appears to accelerate healing of tendons, ligaments, muscles, and the GI tract through multiple pathways including the FAK-paxillin pathway.
Common Uses
- Tendon and ligament repair
- Gut healing and GI protection
- Muscle injury recovery
- Joint health
- Post-surgical recovery
Known Risks
- Limited human clinical trial data
- Most research is animal-based
- Potential interactions with blood pressure medications
- Injection site reactions
- Long-term safety profile unknown
Regulatory Status
On April 15, 2026, the FDA announced BPC-157 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. It is now scheduled for formal PCAC (Pharmacy Compounding Advisory Committee) review on July 23, 2026, to determine whether it should be added to the 503A bulk drug substances list. Removal from Category 2 does not authorize compounding — pharmacies should exercise caution until PCAC issues its recommendation. Previously reclassified to Category 1 in February 2026, a step that is now superseded by this more formal process.
Get notified when the PCAC decides on BPC-157
Scheduled review: July 23, 2026. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
250–500 mcg
Frequency
Once or twice daily
Cycle Length
4–12 weeks
Inject near the injury site when possible. Reconstitute with bacteriostatic water. Refrigerate after reconstitution.
Oral (capsule or liquid)
Typical Dose
500 mcg–1 mg
Frequency
Once daily
Cycle Length
4–12 weeks
Oral bioavailability is lower than injectable but may be preferred for gut-specific conditions. Take on an empty stomach.
Related Compounds
Research References
Related Articles
PCAC July 2026 Results: What the FDA Advisory Committee Decided on 7 Peptides
regulatory · 5 min read
What Happens If the FDA Reverses Course on Peptides
regulatory · 8 min read
What Is BPC-157? Uses, Risks, and FDA Status
guide · 3 min read
How to Submit a Public Comment to the FDA Before July 9 (Step-by-Step)
regulatory · 9 min read
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.